Last updated: August 1, 2026
Sarafem is the former brand name for fluoxetine hydrochloride approved by the U.S. FDA for premenstrual dysphoric disorder, or PMDD. Its regulatory value rests on the PMDD indication, not on a new active ingredient. The brand has no meaningful current clinical-development pipeline, its original regulatory exclusivity has expired, and fluoxetine is widely available as a generic. Commercial growth is therefore concentrated in generic fluoxetine used for PMDD rather than in Sarafem-branded sales.
What is Sarafem and what is it approved to treat?
Sarafem contains fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, or SSRI. The FDA approved it for the treatment of PMDD in July 2000. The approved labeling covers both continuous daily dosing and intermittent dosing during the luteal phase of the menstrual cycle (U.S. Food and Drug Administration [FDA], 2000).
Sarafem is distinct from Prozac in branding and indication positioning, but the active ingredient is the same.
| Attribute |
Sarafem |
| Active ingredient |
Fluoxetine hydrochloride |
| Drug class |
SSRI |
| Original sponsor |
Eli Lilly and Company |
| FDA approval |
July 2000 |
| Approved indication |
PMDD |
| Dosage strengths |
10 mg and 20 mg tablets |
| Administration |
Continuous or intermittent luteal-phase dosing |
| Regulatory pathway |
Full NDA approval |
| Current competitive status |
Generic fluoxetine and other PMDD therapies |
| Biosimilar exposure |
None, because Sarafem is a small-molecule drug |
The label describes PMDD as a severe form of premenstrual syndrome with affective, behavioral and physical symptoms that interfere with functioning. The diagnosis requires prospective confirmation of symptoms across menstrual cycles.
What clinical trials supported Sarafem approval?
The Sarafem approval was supported by randomized, placebo-controlled trials of fluoxetine in women with PMDD. The studies evaluated symptom improvement using prospective daily symptom ratings and included both continuous and intermittent dosing approaches.
The FDA label reports that fluoxetine improved PMDD symptoms compared with placebo. Evidence supported a 20 mg daily dose. The label also states that 10 mg did not demonstrate the same level of efficacy as 20 mg in the pivotal PMDD program (FDA, 2000).
Key clinical findings included:
| Clinical issue |
Sarafem evidence |
| Target population |
Women meeting PMDD diagnostic criteria |
| Comparator |
Placebo |
| Primary clinical focus |
Mood, irritability, tension, affective symptoms and functional impairment |
| Effective dose |
20 mg daily |
| Dosing strategy |
Continuous and luteal-phase dosing |
| Main safety concerns |
Nausea, insomnia, somnolence, anxiety, nervousness, headache and sexual dysfunction |
| Long-term risk considerations |
SSRI withdrawal symptoms, serotonin syndrome, suicidality warnings and drug interactions |
The PMDD program did not establish a new pharmacologic mechanism. It demonstrated that fluoxetine, an established antidepressant, could treat the cyclical symptom pattern associated with PMDD.
What is the current clinical-trial status of Sarafem?
Sarafem has no identifiable active late-stage clinical-development program. The clinical evidence base is historical and supports an established generic indication rather than an ongoing branded development strategy.
Current research involving fluoxetine and PMDD is more likely to address comparative effectiveness, symptom measurement, treatment sequencing, reproductive health, or combination therapy than to support a new Sarafem approval. Studies may also examine SSRIs in broader premenstrual disorders, but those studies do not create new exclusivity for Sarafem.
Are there active Phase 3 Sarafem trials?
No active Phase 3 program is associated with the Sarafem brand. The original PMDD efficacy program is complete, and the indication is available through generic fluoxetine.
Are new formulations of Sarafem in development?
There is no established current development program for a differentiated Sarafem formulation. Potential formulation strategies, such as extended-release delivery, combination products or digital adherence support, would face a limited commercial incentive because generic fluoxetine is inexpensive and widely prescribed.
What is the FDA regulatory status of Sarafem?
Sarafem received FDA approval under an NDA for fluoxetine hydrochloride tablets. The approval established PMDD as a labeled indication for the branded product.
The regulatory position has changed materially since approval:
- The original brand approval remains historically important for the PMDD indication.
- The active ingredient is available from multiple generic manufacturers.
- Sarafem does not have an active biologic-license framework or biosimilar pathway.
- Generic fluoxetine can be prescribed for PMDD where the product labeling and payer practices permit.
- A product discontinued from commercial distribution can remain in FDA databases without representing an active commercial brand.
The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, is the primary source for current listed products, patents and exclusivity. Because fluoxetine has long been generic, the commercial question is generic availability rather than brand protection (FDA, 2024a).
What patents protect Sarafem and when did exclusivity expire?
Sarafem’s original patent and regulatory advantages have expired. The principal active ingredient, fluoxetine, was developed and commercialized decades before Sarafem’s PMDD approval. The relevant basic compound and early product protection did not prevent generic fluoxetine entry after the early 2000s.
Sarafem’s commercial protection depended more heavily on the PMDD indication, labeling and regulatory exclusivity than on a durable composition-of-matter patent. The original approval occurred in 2000, and the relevant three-year new clinical investigation exclusivity period would have ended in 2003, subject to the specific approved application and FDA exclusivity records.
| Protection category |
Sarafem position |
| Composition-of-matter protection |
Expired |
| Basic fluoxetine product protection |
Expired |
| PMDD indication exclusivity |
Expired |
| Regulatory exclusivity |
Expired |
| Current Orange Book blocking patent |
No commercially meaningful active protection expected |
| Generic entry |
Established |
| Biosimilar protection |
Not applicable |
Does Sarafem have formulation or method-of-use patent protection?
No active, commercially significant formulation or method-of-use barrier is generally associated with Sarafem. A party could theoretically pursue a patent on a new formulation, dosing regimen or combination therapy, but such a patent would protect only the claimed innovation. It would not restore exclusivity over ordinary fluoxetine tablets or capsules.
A dosing patent would also face challenges involving obviousness, written description, enablement and clinical relevance. Intermittent luteal-phase dosing was already part of the historical PMDD evidence base, reducing the opportunity to obtain broad new protection over that strategy.
Are there Paragraph IV challenges against Sarafem?
Paragraph IV litigation is not a current commercial risk for Sarafem. Generic fluoxetine entered the market years ago, and the principal barriers associated with the original product have expired.
A Paragraph IV certification is relevant when an ANDA applicant challenges an unexpired Orange Book-listed patent. For Sarafem, the practical market outcome is already generic competition. Any future Paragraph IV dispute would more likely concern a new fluoxetine formulation or a separate sponsor’s later patent than the original Sarafem product.
What is the current market for Sarafem and generic fluoxetine?
The Sarafem-branded market is small or commercially inactive compared with the broader fluoxetine market. Generic fluoxetine is used across major psychiatric indications, including major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder and PMDD. PMDD represents only a portion of total fluoxetine utilization.
The market has several structural characteristics:
| Market factor |
Commercial effect |
| Generic availability |
Suppresses price and brand revenue |
| Multiple manufacturers |
Increases substitution and payer leverage |
| Low manufacturing complexity |
Limits entry barriers |
| Established physician familiarity |
Supports continued use |
| PMDD diagnostic variability |
Limits addressable diagnosed volume |
| Competing SSRIs |
Constrains share |
| Oral tablet and capsule formats |
Offer little differentiation |
| Low treatment cost |
Reduces room for premium pricing |
Sarafem also faced a branding challenge because the product used a distinct name and pink tablet presentation for a drug already associated with Prozac. Brand differentiation could support consumer recognition, but it did not create durable pricing power after generic fluoxetine became available.
How does Sarafem compare with competing PMDD treatments?
Sarafem competes primarily with generic SSRIs, combined hormonal contraceptives and nonprescription symptom-management approaches. FDA-approved pharmacologic treatment options for PMDD include certain oral contraceptive products containing drospirenone and ethinyl estradiol. Other SSRIs, including sertraline and paroxetine controlled release, have also been studied or approved for PMDD-related use depending on product and jurisdiction.
| Treatment category |
Strength |
Commercial limitation |
| Fluoxetine |
Long clinical history; continuous or intermittent dosing |
Generic pricing and SSRI tolerability |
| Sertraline |
Strong SSRI evidence; generic availability |
Similar class adverse effects |
| Paroxetine controlled release |
PMDD evidence and branded history |
Weight, sexual and withdrawal concerns |
| Drospirenone/ethinyl estradiol |
Addresses hormonal and contraceptive needs |
Thromboembolic and hormonal risks |
| Cognitive behavioral therapy |
Nonpharmacologic option |
Access and adherence constraints |
| GnRH-based therapy |
Option for severe refractory disease |
Cost, tolerability and hormonal adverse effects |
Fluoxetine has a relatively long half-life, which can reduce the clinical impact of missed doses and discontinuation compared with shorter-acting SSRIs. Its long half-life can also prolong adverse effects and drug-interaction exposure.
What generic entry risks exist for Sarafem?
The risk is not a future generic launch. Generic entry has already occurred. The relevant risks are:
- Continued erosion of any residual brand prescriptions.
- Therapeutic substitution to sertraline, paroxetine or hormonal therapies.
- Reimbursement policies favoring low-cost generic fluoxetine.
- Manufacturer consolidation or temporary supply disruptions.
- Reduced physician use of a brand-specific PMDD label.
- Off-label use of generic fluoxetine without Sarafem branding.
Manufacturing barriers are modest. Fluoxetine tablets and capsules use mature pharmaceutical technology, and the active ingredient is widely manufactured. A new entrant would still need FDA approval, bioequivalence data, current good manufacturing practice compliance and reliable supply, but those requirements do not create a high barrier relative to complex drugs or biologics.
What is the commercial outlook and revenue projection for Sarafem?
Sarafem-branded revenue has limited upside. A realistic base case is near-zero or immaterial brand revenue, with commercial activity concentrated in generic fluoxetine.
Base-case projection
| Period |
Sarafem brand outlook |
Generic fluoxetine PMDD outlook |
| 2024-2025 |
Minimal branded activity |
Stable prescription demand |
| 2026-2028 |
No material recovery expected |
Low single-digit volume growth possible |
| 2029 onward |
Brand remains commercially marginal |
Mature, price-competitive market |
The principal growth drivers are increased PMDD diagnosis, improved recognition of premenstrual disorders and expanded access to mental-health treatment. Offsetting factors include generic price compression, competition from other SSRIs and hormonal therapies, and limited differentiation between manufacturers.
No defensible projection supports a return to the peak commercial profile of the original Sarafem launch. Any meaningful revenue opportunity would require a new product with differentiated delivery, a combination regimen, a validated diagnostic strategy or a newly protected clinical use. Ordinary fluoxetine tablets do not offer that opportunity.
How strong is the Sarafem patent estate?
The Sarafem patent estate is weak as a current commercial asset because the relevant exclusivity periods have expired and generic competition is established.
| Patent-estate criterion |
Assessment |
| Composition protection |
Weak or expired |
| Indication protection |
Expired |
| Formulation protection |
No material current barrier identified |
| Orange Book leverage |
Low |
| Litigation leverage |
Low |
| Manufacturing protection |
Low |
| Licensing value |
Limited |
| Generic vulnerability |
High |
The asset may retain historical value for pharmacology, clinical evidence and PMDD treatment positioning. It has little standalone value as an enforceable exclusivity platform.
Are there licensing deals or active litigation involving Sarafem?
No major current licensing transaction or active litigation is central to the Sarafem commercial outlook. Eli Lilly’s historical role is the principal originator relationship. Any current transactions involving fluoxetine are more likely to concern generic supply, manufacturing, distribution or broader portfolios rather than Sarafem rights.
There is also no meaningful biosimilar litigation pathway because fluoxetine is a chemically synthesized small molecule. Future disputes would most likely involve product quality, supply, advertising, labeling or a newly patented formulation rather than the original Sarafem indication.
Key Takeaways
- Sarafem is fluoxetine hydrochloride marketed for PMDD.
- The FDA approved Sarafem in July 2000.
- Its clinical evidence supported 20 mg fluoxetine, administered continuously or during the luteal phase.
- No active branded clinical-development program supports Sarafem.
- Original patent and regulatory exclusivity have expired.
- Generic fluoxetine has replaced Sarafem as the economically relevant product.
- Paragraph IV litigation is not a current barrier to generic access.
- No biosimilar risk applies.
- The Sarafem brand has minimal revenue recovery potential.
- Future value would require a new, differentiated and patentable fluoxetine-based product.
FAQs about Sarafem
Is Sarafem still available by prescription?
Fluoxetine is widely available by prescription as a generic. Availability of the Sarafem brand itself depends on commercial distribution and pharmacy inventory.
Can generic fluoxetine be used for PMDD?
Yes. Clinicians may prescribe generic fluoxetine for PMDD based on the established fluoxetine evidence base and the patient’s clinical circumstances.
Is Sarafem the same drug as Prozac?
Yes. Both products contain fluoxetine hydrochloride. Their historical branding and labeled indications differed.
What dose of fluoxetine is commonly used for PMDD?
The Sarafem clinical program and FDA labeling identified 20 mg daily as the principal effective dose. Clinicians determine dosing based on response, tolerability and treatment schedule.
Does Sarafem have a biosimilar competitor?
No. Biosimilars apply to biologic products. Sarafem is a small-molecule fluoxetine product, so competition occurs through generic drug approvals.
References
- U.S. Food and Drug Administration. (2000). Sarafem (fluoxetine hydrochloride) tablets prescribing information.
- U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database.
- American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.).
- Halbreich, U., Borenstein, J., Pearlstein, T., Kahn, L. S., & others. (2003). The diagnosis and management of premenstrual dysphoric disorder. CNS Drugs, 17(5), 341-359.
